S&P 500
(0.02%) 5 071.63 points
Dow Jones
(-0.11%) 38 461 points
Nasdaq
(0.10%) 15 713 points
Oil
(-0.06%) $82.76
Gas
(0.36%) $1.659
Gold
(-0.39%) $2 329.30
Silver
(-0.42%) $27.23
Platinum
(-0.21%) $913.90
USD/EUR
(-0.03%) $0.934
USD/NOK
(0.00%) $10.98
USD/GBP
(-0.02%) $0.802
USD/RUB
(0.00%) $92.32

Realtime updates for Cymabay Therapeutics Inc [CBAY]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
95.24%
return 35.11%
SELL
27.27%
return 3.87%
Last Updated21 Mar 2024 @ 16:00

0.00% $ 32.48

BUY 50777 min ago

@ $32.47

Issued: 20 Mar 2024 @ 14:01


Return: 0.03%


Previous signal: Mar 19 - 14:47


Previous signal: Sell


Return: -0.03 %

Live Chart Being Loaded With Signals

Commentary (21 Mar 2024 @ 16:00):

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases...

Stats
Today's Volume 0.00
Average Volume 4.16M
Market Cap 3.73B
EPS $0 ( 2024-03-21 )
Next earnings date ( $-0.320 ) 2024-05-20
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -32.81
ATR14 $0.00700 (0.02%)
Insider Trading
Date Person Action Amount type
2024-03-22 Loewy Caroline M Sell 30 000 Employee Stock Option (right to buy)
2024-03-22 Loewy Caroline M Sell 15 000 Employee Stock Option (right to buy)
2024-03-22 Loewy Caroline M Sell 7 500 Employee Stock Option (right to buy)
2024-03-22 Loewy Caroline M Sell 16 000 Employee Stock Option (right to buy)
2024-03-22 Loewy Caroline M Sell 27 705 Employee Stock Option (right to buy)
INSIDER POWER
-97.48
Last 100 transactions
Buy: 127 470 | Sell: 9 848 383

Volume Correlation

Long: -0.17 (neutral)
Short: -0.63 (weak negative)
Signal:(46.979) Neutral

Cymabay Therapeutics Inc Correlation

10 Most Positive Correlations
XPDB0.96
ROCL0.956
HWEL0.955
IXAQ0.953
GDNR0.953
ARTEU0.952
VMGA0.952
FNVT0.952
AVAC0.951
PWUP0.951
10 Most Negative Correlations
RMRM-0.983
ASPS-0.952
BFC-0.945
EVLO-0.943
CLFD-0.942
CREG-0.941
YJ-0.941
STAB-0.941
SYBT-0.939
MMAT-0.936

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cymabay Therapeutics Inc Correlation - Currency/Commodity

The country flag 0.00
( neutral )
The country flag -0.25
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.01
( neutral )

Cymabay Therapeutics Inc Financials

Annual 2023
Revenue: $31.07M
Gross Profit: $30.39M (97.81 %)
EPS: $-0.990
Q4 2023
Revenue: $57 000.00
Gross Profit: $1 000.00 (1.75 %)
EPS: $-0.370
Q3 2023
Revenue: $0
Gross Profit: $-215 000 (0.00 %)
EPS: $-0.320
Q2 2023
Revenue: $31.02M
Gross Profit: $30.81M (99.32 %)
EPS: $-0.00790

Financial Reports:

No articles found.

Cymabay Therapeutics Inc

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators